Lexaria Bioscience Corp. Announces 2024 Annual Shareholder Meeting Details

TL;DR

<b>Lexaria Bioscience Corp. has scheduled its 2024 annual shareholder meeting for April 23, 2024, encouraging proxy voting or virtual attendance.</b>

AI Summary

Lexaria Bioscience Corp. (LEXX) filed a Proxy Statement (DEF 14A) with the SEC on March 6, 2024. Lexaria Bioscience Corp. will hold its 2024 annual shareholder meeting on April 23, 2024, at 1:00 p.m. (PT). The meeting will be conducted via Event Conferencing, with dial-in numbers provided for Toronto residents and toll-free access. Shareholders are strongly encouraged to vote by proxy or attend the meeting. The filing is a Definitive Proxy Statement (DEF 14A) filed on March 6, 2024. The company's common stock is listed on the Nasdaq under the ticker symbols LEXX and LEXXW.

Why It Matters

For investors and stakeholders tracking Lexaria Bioscience Corp., this filing contains several important signals. This filing provides shareholders with essential information regarding the upcoming annual meeting, including the date, time, and method of participation, allowing them to exercise their voting rights. The DEF 14A filing serves as a formal communication to shareholders about corporate governance matters and upcoming decisions to be made at the meeting.

Risk Assessment

Risk Level: low — Lexaria Bioscience Corp. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Shareholders should review the proxy materials to understand the proposals being voted on and cast their votes accordingly, either by proxy or by attending the virtual meeting.

Key Numbers

• April 23, 2024 — Annual Meeting Date (2024 annual shareholder meeting date)
• 1:00 p.m. (PT) — Annual Meeting Time (2024 annual shareholder meeting time)
• 20240306 — Filing Date (DEF 14A filing date)
• Nasdaq — Exchange Listing (Stock exchange listing)

Key Players & Entities

• Lexaria Bioscience Corp. (company) — Registrant name
• Chris Bunka (person) — Director, CEO & Chairman
• John Docherty (person) — Director & President
• Nicholas Baxter (person) — Director
• William (Ted) McKechnie (person) — Director
• Albert Reese Jr. (person) — Director
• Dr. Catherine C. Turkel (person) — Director
• Computershare Investor Services (company) — Registrar and Transfer Agent

FAQ

Industry Context

Lexaria Bioscience Corp. operates in the pharmaceutical preparations industry, focusing on developing and commercializing technology for enhanced drug delivery.

Regulatory Implications

The company is subject to SEC regulations governing proxy solicitations and shareholder communications, as evidenced by this DEF 14A filing.

What Investors Should Do

1. Review the proxy statement for details on proposals and director nominees.
2. Vote your shares by proxy or attend the virtual annual meeting.
3. Note the dial-in information for the virtual meeting on April 23, 2024.

Key Dates

• 2024-04-23: Annual Shareholder Meeting — Shareholders will vote on corporate matters and elect directors.
• 2024-03-06: DEF 14A Filing — Definitive Proxy Statement filed with the SEC.

Year-Over-Year Comparison

This filing is a routine DEF 14A for the annual meeting and does not contain comparative financial data from a previous filing.

Key Financial Figures

• $0.001 — h full voting rights and a par value of $0.001 per share. As of the Record Date a tota

Filing Documents

• lxrp_def14a.htm (DEF 14A) — 436KB
• lxrp_def14aimg1.jpg (GRAPHIC) — 10KB
• lxrp_def14aimg2.jpg (GRAPHIC) — 173KB
• lxrp_def14aimg3.jpg (GRAPHIC) — 125KB
• lxrp_def14aimg4.jpg (GRAPHIC) — 171KB
• lxrp_def14aimg5.jpg (GRAPHIC) — 182KB
• 0001640334-24-000357.txt (&nbsp;) — 1349KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 5 DIRECTOR NOMINEES 6 Board Diversity 7 Business Experience 8 Executive Officers 9 Family Relationships 9 Involvement in Certain Legal Proceedings 9 Corporate Governance 10 Committees of the Board of Directors 12 AUDIT AND FINANCE COMMITTEE REPORT 13 Director Independence 13 Shareholder Communications with Our Board of Directors 13 Board Leadership Structure 14 Section 16(a) Beneficial Ownership Reporting Compliance 14

Executive Compensation

Executive Compensation 14 i Table of Contents Compensation Discussion and Analysis 16 Compensation Plans 20 Pay vs Performance 22 Compensation of Directors 23 Securities Authorized for Issuance under Equity Compensation Plans 24 Transactions with Related Persons and Related Person Transaction Policy 24 Employment Agreements 24 Fees Paid to Our Independent Registered Public Accounting Firm 24 PROPOSALS FOR SHAREHOLDER VOTE 26 Proposal 1 Election of Directors 26 Proposal 2 Ratification of the Continued Appointment of the Independent Registered Public Accounting Firm 26 Proposal 3 Ratification and Approval of Acts of the Directors 27 INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON 27 "HOUSEHOLDING" OF PROXY MATERIALS 27 SHAREHOLDER PROPOSALS 27 WHERE YOU CAN FIND MORE INFORMATION 28 SOLICITATION OF PROXIES 28 OTHER MATTERS 28 ii Table of Contents LEXARIA BIOSCIENCE CORP. 100 – 740 McCurdy Road Kelowna, BC, Canada V1X 2P7 Telephone: (250) 765-6424 PROXY STATEMENT ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 23, 2024 GENERAL INFORMATION ABOUT THE MEETING OF SHAREHOLDERS The Board of Directors of Lexaria Bioscience Corp. (" Lexaria ", " we ", " us " or " our ") is soliciting proxies for use at the Annual Meeting of Shareholders to be held via Event Conferencing by way of calling: for Toronto residents (416) 764-8658 ; and for all others 1-888-886-7786 , at 1:00 p.m. (PT), on Tuesday, April 23, 2024 or at any adjournment of the Annual Meeting (the " Meeting "). This proxy statement, the attached notice of the Meeting, a proxy card and our Annual Report on Form 10-K for the year ended August 31, 2023, as filed with the Securities and Exchange Commission on November 20, 2023 are collectively referred to as the " proxy materials ". The proxy materials are first being made available to our shareholders on or about March 6, 2024. Important Notice Regarding the Internet Availability of Pr

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management The following table sets forth, as of the Record Date, certain information with respect to the beneficial ownership of our common shares by each shareholder known by us to be the beneficial owner of more than 5% of our common shares, as well as by each of our current Directors and executive officers as a group. Each person has sole voting and investment power with respect to the common shares, except as otherwise indicated. Beneficial ownership consists of a direct interest in the common shares, except as otherwise indicated. Name, Address & Position of Beneficial Owner (1)(2) Amount and Nature of Beneficial Percentage of Class (3) Directors and Executive Officers as a Group 969,307 7.61 % Executive Officers and Directors Individually Christopher Bunka CEO, Chairman & Director 658,956 (4) 5.27 % John Docherty President and Director 178,743 (5) 1.43 % Nicholas Baxter* Independent Director 46,000 (6) 0.37 % Ted McKechnie* Independent Director 48,191 (7) 0.39 % Albert Reese Jr.* Independent Director 25,917 (8) 0.21 % Dr. Catherine C. Turkel* Independent Director 11,500 (9) 0.09 % 5% Owners N/A * denotes a holding of less than 1% Notes: 1) Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) withi